(One intermediate revision by the same user not shown)
Line 1:
#REDIRECT [[Heart_transplantation#Complications]]
'''AlloMap molecular expression testing''', developed and commercialized by CareDx, formerly known as XDx, is a gene expression profiling test to identify [[heart transplantation|heart transplant]] recipients with a low probability of one type of [[organ transplant|transplant]] rejection. The test is performed on a [[blood]] sample, providing a non-invasive test to help manage the care of patients post transplant. Prior to the availability of this test, the primary method for managing heart [[transplant rejection]] was the invasive technique of endomyocardial biopsy.
AlloMap was cleared by the U.S. [[Food and Drug Administration]] (FDA) in 2008 as a Class II Medical Device.<ref>http://www.accessdata.fda.gov/cdrh_docs/reviews/K073482.pdf</ref> It is available only from the CareDx Reference Laboratory in Brisbane, CA.
The use of the test is described in the recommendations for the non-invasive monitoring of acute heart transplant rejection in the first evidence-based clinical practice guidelines for the care of heart transplant recipients issued by the International Society of Heart and Lung Transplantation.<ref>{{cite journal |last1=Costanzo |first1=MR |last2=Costanzo |first2=MR |last3=Dipchand |first3=A |last4=Starling |first4=R |last5=Anderson |first5=A |last6=Chan |first6=M |last7=Desai |first7=S |last8=Fedson |first8=S |last9=Fisher |first9=P |displayauthors=8|title=The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients |journal=The Journal of Heart and Lung Transplantation |volume=29 |issue=8 |pages=914–56 |year=2010 |pmid=20643330 |doi=10.1016/j.healun.2010.05.034}}</ref>
